- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00209586
A Study of AQUAVAN® Injection for Sedation in Elderly Patients Undergoing Flexible Bronchoscopy
A Phase III, Randomized, Open-label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Flexible Bronchoscopy Procedures
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, open-label study designed to assess the safety and efficacy of AQUAVAN® Injection versus midazolam HCl following pretreatment with an analgesic, fentanyl citrate injection, in producing sedation in patients undergoing a flexible bronchoscopy procedure. Randomization will be stratified by site. Following completion of pre-procedure sedation assessments, patients will be randomly assigned to 1 of the 2 i.v. treatment groups at a 3:1 (AQUAVAN® Injection: midazolam HCl) allocation ratio.
All study patients, irrespective of treatment group assignment, will receive fentanyl citrate injection as an analgesic pretreatment. Supplemental doses of fentanyl citrate injection may be administered if the patient reports pain or if inadequate analgesia is present as demonstrated by increased heart rate and/or blood pressure in the presence of adequate sedation. At no time should fentanyl citrate injection be administered to increase sedation levels. AQUAVAN® Injection and midazolam HCl will be administered to induce a state of adequate sedation, defined as a Modified Observer's Assessment of Alertness / Sedation (OAA/S) score of 4 or less. Supplemental doses will be administered to increase depth or duration of sedation. Supplemental doses will not be administered if the Modified OAA/S score is 2 or less or if there is no purposeful response to stimulation. The depth of sedation will be measured by the Modified OAA/S scale, a validated measure. Patient and Investigator assessments will be used to confirm that the depth of sedation provided met the goals of sedation, reduction of anxiety and reduced awareness.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient provided signed/dated Informed Consent and HIPAA Authorization after receiving a full explanation of the extent and nature of the study.
- Patient was at least 18 years of age at the time of screening.
- Female patient must have been surgically sterile, postmenopausal, or not pregnant or lactating, and must have been using an acceptable method of birth control for at least 1 month prior to dosing, with a negative urine pregnancy test result at screening and predosing periods.
- Patient met the American Society of Anesthesiologists (ASA) Physical Status Classification of I to III.
Exclusion Criteria:
- Patient had a history of allergic reaction or hypersensitivity to any anesthetic agent, narcotic or benzodiazepine.
- Patient did not meet nils per os (NPO) status per ASA Guideline or institution's guideline.
- Patient had condition(s) that, in the opinion of the Investigator, could interfere with appropriate airway management.
- Patient required artificial ventilation prior to the initiation of bronchoscopy or was admitted to the intensive care unit.
- Patient had a history of mental or visual impairment that would not permit successful measurement of cognitive evaluations.
- Patient was unwilling to adhere to pre- and postprocedural instructions.
- The use of fentanyl or midazolam was contraindicated for the patient.
- Patient had participated in an investigational study within 1 month prior to study start.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Sedation success defined for a patient as having 3 consecutive Modified OAA/S scores <=4 and completing the procedure without requiring alternative sedative medications and without requiring manual or mechanical ventilation.
|
Secondary Outcome Measures
Outcome Measure |
---|
Change from baseline DSST score over time during recovery period
|
Secondary Efficacy Endpoints
|
Time to Fully Recovered from end of procedure
|
Time to Fully Alert from end of procedure
|
Modified OAA/S scores over time during the dosing initiation, procedural, and recovery periods
|
Duration and percent of time when a patient's Modified OAA/S score is at each level between the first dose of study medications and Fully Alert, inclusive
|
Duration of sedation
|
Number of doses of study medication administered for the procedure
|
Time to sedation
|
Number of procedure interruptions due to inadequate sedation
|
Patient's rating of experience after Fully Recovered
|
Patient's rating at 24 hour post-discharge telephone survey
|
Investigator's rating at end of procedure
|
Blinded evaluator's rating after patient is Fully Recovered
|
Safety Endpoints
|
Nature, frequency, severity, relationship to treatment, and outcome of all adverse events
|
Sedation-related adverse events and interventions
|
Laboratory parameters and vital signs
|
Airway assistance
|
Concomitant medications
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: James Jones, MD, PharmD, Eisai Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3000-0409
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Flexible Bronchoscopy
-
RWTH Aachen UniversityUnknownFlexible BronchoscopyGermany
-
Chang Gung Memorial HospitalCompleted
-
National University of MalaysiaCompletedFlexible BronchoscopyMalaysia
-
Chang Gung Memorial HospitalTerminatedFlexible BronchoscopyTaiwan
-
The Cooper Health SystemCompletedSedation | COPD | Flexible BronchoscopyUnited States
-
Rabin Medical CenterSuspendedPaediatric Flexible Bronchoscopy
-
RWTH Aachen UniversityUnknown
-
Copenhagen University Hospital at HerlevUnknownSedation | Satisfaction | Safety | Flexible BronchoscopyDenmark
-
Peking University People's HospitalTibet Autonomous Region People's HospitalCompletedIntubation Time | Simulation Training | Flexible BronchoscopyChina
-
Postgraduate Institute of Medical Education and...CompletedPatients With Indication for Flexible BronchoscopyIndia
Clinical Trials on fospropofol disodium
-
West China HospitalCompleted
-
Eisai Inc.Omnicare Clinical Research; MDS Pharma Services; Bio Analytical Research Corporation and other collaboratorsCompletedColonoscopy | Colon Polyps
-
Eisai Inc.CompletedIntubation | Respiration, Artificial | Postoperative SedationUnited States
-
Eisai Inc.CompletedAnesthesia | BronchoscopyUnited States
-
Eisai Inc.PPD; Covance; Quest Pharmaceutical ServicesTerminated
-
Eisai Inc.PPD; MDS Pharma Services; Bio Analytical Research Corporation; Coghlan Group (Plasma...CompletedColonoscopy | Colon Polyps
-
Eisai Inc.PPD; CovanceCompletedAngioplasty | Coronary Catheterization
-
Eisai Inc.PPD; CovanceTerminatedOsteotomy | Carpal Tunnel | Arthroscopy | Bunionectomy
-
Eisai Inc.CompletedProcedural SedationUnited States